Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg adjunctive therapy in dermatomyositis and polymyositis
2005-002463-88Phase 3Completed
- Sponsor
- Orphagen Therapeutics
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) and polymyositis (PM) comparing Ig VENA adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2005; status: completed.
02
Drugs
Gamimune-N
03
Conditions
dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on 2005-002463-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002463-88.